LGND — LIGAND PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 886163 ·
Last close
$293.81
Market Cap
$5.86B
52W High
$326.63
52W Low
$175.89
ADV30
222,362
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 78,746,000 76,096,000 -9,491,000 -28,485,000 2,237,462,000 55,958,000 1,275,699,000
Jun 2026 63,693,000 60,479,000 8,591,000 48,508,000 2,185,875,000 1,006,702,000 1,218,359,000
Mar 2026 51,722,000 48,449,000 17,368,000 -13,345,000 1,532,105,000 115,077,000 534,783,000
Dec 2025 59,666,000 56,674,000 20,040,000 44,784,000 1,560,637,000 174,927,000 543,425,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$131,714,000
Investing CF
$-144,779,000
Financing CF
$950,276,000
CapEx
$-11,959,000
Dividends Paid
—
Buybacks
$-15,000,000
EPS Diluted TTM
$9.35
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$583,251,000
Inventory
$8,663,000
Receivables
$69,922,000
ST Investments
$364,038,000
EBIT TTM
$244,152,000
Pretax Income TTM
$237,962,000
Interest Exp TTM
$6,190,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$306,899,008
EBITDA
$117,036,000
Free Cash Flow
$139,748,880
Enterprise Value
$7,123,557,376
Total Cash
$447,395,008
Total Debt
$1,128,216,960
Shares Out
19,935,609
Trailing EPS
$9.49
Book Value
$48.57
ROE
5.4%
ROA
2.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 268,087,000 47,199,000 124,453,000 1,560,637,000 543,425,000 1,017,212,000 49,359,000
Dec 2024 167,133,000 23,021,000 -4,032,000 941,774,000 111,335,000 830,439,000 97,047,000
Dec 2023 131,314,000 9,821,000 52,154,000 787,216,000 86,303,000 700,913,000 49,577,000
Dec 2022 196,245,000 3,037,000 -33,361,000 762,668,000 165,183,000 597,485,000 137,850,000

TTM Snapshot

Revenues TTM
$290,542,000
NetIncome TTM
$197,220,000
OpCashFlow TTM
—
Assets (Latest)
$2,185,875,000
Forward EPS
$11.96

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $290.00 · spot: $298.71 · call volume: 95 · put volume: 66

Peers — same industry

TickerNameMarket CapLastDaily %
MIRM Mirum Pharmaceuticals, Inc. $6.00B $91.95 —
ARWR ARROWHEAD PHARMACEUTICALS, INC. $6.08B $42.99 —
BLTE BELITE BIO, INC $6.35B $157.72 —
GIFLF Grifols SA $5.37B $12.72 —
MANE Veradermics, Inc $5.30B $125.64 —

News headlines (Yahoo Finance, 1h cache)

Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer Says
2026-10-30 17:12 · Yahoo
Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty Strength
2026-10-30 17:09 · Yahoo
Ligand (LGND) Q3 2026 Earnings Call Transcript
2026-10-30 14:46 · Yahoo
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
2026-10-29 19:14 · Yahoo
Ligand: Q3 Earnings Snapshot
2026-10-29 11:20 · Yahoo
Ligand Reports Third Quarter 2026 Financial Results
2026-10-29 11:00 · Yahoo
Ligand to Participate in November Investor Conferences
2026-10-27 20:01 · Yahoo
Ligand to Host Investor Day on December 8, 2026
2026-10-22 20:01 · Yahoo
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
2026-10-19 15:42 · Yahoo
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
2026-10-15 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.